linjc16/ctgov huggingface dataset:
Epidemiological Study on the Management of Out-of-hospital Cardiac Arrest Survivors in Champagne ArDEnnes

Study Overview
=================
Brief Summary
-----------------
Out-of-hospital cardiac arrest (OHCA) is a public health problem, affecting 50,000 people per year in France. Intervention time (initiation of cardiopulmonary resuscitation (CPR) and advanced CPR) are associated with a better prognosis. Despite this, the latest published data show a very low overall survival (5%). Our territory has only three centers distributed hospitals with both a 24-hour coronary angiography platform and an intensive care unit. Finally, although 60% of ACEHs receive coronary angiography in the Île de France region, it is performed on only 15% of patients in the Reims University Hospital. Therefore, it seems essential to conduct a study on the reality of the support of ACEH and to study the clinical and biological factors as well as the influence of the geographical distribution of specialized technical platforms on the prognosis of patients.

Official Title
-----------------
Epidemiological Study on the Management of Out-of-hospital Cardiac Arrest Survivors in Champagne ArDEnnes

Conditions
-----------------
Out-of-hospital Cardiac Arrest

Intervention / Treatment
-----------------
* Other: observational


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient victim of ACEH in the Champagne-Ardenne region admitted living in hospital. Exclusion Criteria: patient under the age of 18

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cohort<br>Patient present in the SAU after an extra-hospital cardiac arrest | Other: observational<br>* Collect from a bank of biological samples, identification of prognostic factors associated with survival without serious neurological heavy sequelae<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analysis of prognostic factors associated with survival without severe neurological sequelae (CPC 1-2) at 3 months among the following variables |  | 3 months | 
| Analysis of prognostic factors associated with survival without severe neurological sequelae (CPC 1-2) with collection of a bank of biological samples, identification of clinical factors and targeted temperature control |  | 12 months |
Safety Study of F2695 SR in Major Depressive Disorder

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the long- term safety of F2695-SR in the treatment of adults with major depressive disorder.

Official Title
-----------------
A Long-Term, Open-label Extension Study of F2695 SR in Adult Patients With Major Depressive Disorder

Conditions
-----------------
Major Depressive Disorder

Intervention / Treatment
-----------------
* Drug: F2695 SR


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Completed 1 of the lead-in studies LVM-MD-01, LVM-MD-02, or LVM-MD-03 Have normal examination findings at the final visit of the lead-in study Have a negative serum pregnancy test at the final visit of the lead-in study if a woman of child-bearing potential Exclusion Criteria: Any exclusionary psychiatric or medical condition that developed during the lead in study Patients considered a suicide risk Women who are pregnant, breastfeeding, or planning to become during the study OR are sexually active and not currently using a medically acceptable method of contraception

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>(Open-label) F2695 SR capsules, oral administration, once daily, flexible dosing | Drug: F2695 SR<br>* Drug F2695 SR (flexible dose) to be given orally in capsule form once daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events, clinical laboratory tests, vital sign measurements, electrocardiograms, physical examinations, Columbia-Suicide Severity Rating Scale |  | 48 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Depression, Major Depressive Disorder
MIYOPERİCYTOMA OF ORAL MUCOSE: CASE REPORT

Study Overview
=================
Brief Summary
-----------------
Miyopericytoma (MPC) is defined as a benign tumor consisting mostly of oval-spindle-shaped myoid-appearing cells with perivascular growth. It may involve a single or multiple anatomical regions and may be multifocal and tends to occur mainly in the extremities, dermal and superficial soft tissues of adults. Cases of miyopericytoma due to trauma have been reported.Histological features and clinical course are generally benign, but features suggestive of low-grade malignancy were seen in MPCs. Myopericytoma in the oral and maxillofacial region is rare and a limited number of cases have been reported in the literature. A 42-year-old female patient was admitted to our clinic with an enlarging lesion on the lingual aspect of the anterior mandible, which she noticed 2 years ago. As a result of the examination, a smooth-surfaced, off-white, pedunculated, fibrotic, painless, and non-bleeding lesion was detected in the lingual aspect of the anterior mandible. The lesion was removed by excisional biopsy.

Official Title
-----------------
A RARE TUMOR OF THE ORAL MUCOSE, MIYOPERİCYTOMA: CASE REPORT

Conditions
-----------------
Myopericytoma

Intervention / Treatment
-----------------
* Procedure: biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with a fibrotic lesion in the mouth Exclusion Criteria: Patient without fibrotic lesions in the mouth.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: biopsy|biopsy to identify the lesion in the oral mucosa|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| biopsy | We evaluated the extracted biopsy material with histological parameter. | 2 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| recurrence | Clinical parameter | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
oral pathology, mıyopericytoma
Treatment of Early Nasal Polyposis With Topical Triamcinolone

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the effectiveness of intranasal Triamcinolone delivered through a bio-absorbable nasal dressing verses oral steroids and a saline soaked dressing, in the treatment and prevention of early nasal polyposis.

Detailed Description
-----------------
nasopore, a bio-absorbable nasal dressing, may offer an alternative route of sustained steroid drug delivery. The use of topical targeted intranasal steroids may prevent the routine adverse effects of oral steroids while maintaining the same therapeutic / clinical efficacy.

Official Title
-----------------
Treatment of Early Nasal Polyposis With Topical Triamcinolone

Conditions
-----------------
Nasal Polyps

Intervention / Treatment
-----------------
* Drug: Triamcinolone
* Drug: Saline soaked sponge


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years Patients with early nasal polyposis Exclusion Criteria: Age < 18 years Patients with active sinus infections Patients on long term steroids Allergy or sensitivity to steroids Patients with Antrochoanal polyps Patients who received topical steroids by bio-resorbable sponge or oral steroids

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Interventional Model Description: Patients will be randomized into 2 study groups, experimental and control.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Triamcinolone<br>Triamcinolone soaked nasopore dressing | Drug: Triamcinolone<br>* Triamcinolone soaked nasopore dressing<br>* Other names: Kenalog (40);|
| Placebo Comparator: Control Group<br>Saline soaked sponge | Drug: Saline soaked sponge<br>* saline soaked sponge<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Nasal Endoscopic Exam Findings . | nasal endoscopic exam findings at 2 weeks, 6 weeks and 12 weeks were not collected from any participant. | 2 weeks, 6 weeks, 12 weeks were not collected from any participant. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Treatment
COVID-19 Phobia in Patients With Bronchiectasis During Covid-19 Pandemic

Study Overview
=================
Brief Summary
-----------------
In the literature, there are no studies evaluating COVID-19 phobia, quality of life, health anxiety, physical activity level and quality of sleep in patients with bronchiectasis during COVID-19 pandemic. The investigators will evaluate these parameters in patients with bronchiectasis and compare the findings of healthy individuals during COVID-19 pandemic

Official Title
-----------------
COVID-19 Phobia and Quality of Life in Patients With Bronchiectasis During Covid-19 Pandemic

Conditions
-----------------
Covid19, Bronchiectasis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Having been diagnosed with non-cystic fibrosis bronchiectasis No acute bronchiectasis exacerbation or infection in the past 2 weeks Volunteering to participate in the research Exclusion Criteria: Having a cognitive problem Not being literate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Bronchiectasis<br>Having been diagnosed with non-cystic fibrosis bronchiectasis | |
| Healthy individuals<br>Healthy individuals without chronic disease | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| COVID-19 Phobia | COVID-19 phobia was evaluated with COVID-19 Phobia Scale (C19P-S) and total score ranges from 20-100. Lower scores mean better outcome. | 5 minutes | 
| Qol | Quality of life was evaluated with Nottingham Health Profile | 10 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Health anxiety | Health anxiety was evaluated with Health Anxiety Inventory | 10 minutes | 
| Physical activity | Physical activity level was evaluated with International Physical Activity Questionnaire - Short Form (IPAQ-SF) | 5 minutes | 
| Quality of sleep | Quality of sleep was evaluated with Pittsburgh Sleep Quality Index | 10 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
phobia, quality of life, health anxiety
Acute Lymphoblastic Leukemia Relapse in Sweden 2003-2007

Study Overview
=================
Brief Summary
-----------------
A minority of patients with adult acute lymphoblastic leukemia (ALL) relapse are rescued. The aim of this population-based study was to assess the results of reinduction treatment and allogeneic stem cell transplantation (SCT) in second complete remission (CR) in Sweden 2003-2007.

Detailed Description
-----------------
This is a national, multicenter, prospective, population-based study of outcome among adult patients aged 19 to 65 years with ALL relapse diagnosed during 2003-2007 in Sweden. Most of the patients had primary treatment according to National guidelines for ALL as recommended by The Swedish Adult ALL Group (SVALL). The guidelines suggest two different treatment protocols for early relapses, and retreatment according to the initial therapy for late relapses, with the intention to proceed to allogeneic SCT in CR2 for eligible patients. The aim of the current study was to assess outcome among adult patients after first ALL relapse, and the utilization and efficacy of recommended protocols and of allogeneic SCT in this setting.

Official Title
-----------------
High Curability Via Intensive Reinduction Chemotherapy and Stem Cell Transplantation in Young Adults With Relapsed Acute Lymphoblastic Leukemia in Sweden 2003-2007

Conditions
-----------------
Acute Lymphoblastic Leukemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients with first relapse of ALL Exclusion Criteria: patients with Burkitt leukemia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 66 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
acute lymphoblastic leukemia, relapse, salvage, prognostic
Evaluation of CTA on the Assessment of Brain Death

Study Overview
=================
Brief Summary
-----------------
At present, different countries have different standards for the diagnosis of brain death, but according to the classic brain death confirmation test, it needs to be combined with transcranial Doppler, EEG, evoked potential and apnea test in clinical practice. Some patients cannot undergo a complete clinical examination and apnea test due to certain factors, and the determination of brain death is limited. The American Academy of Neurology (AAN) guidelines regard cerebral angiography as an acceptable auxiliary examination and is widely regarded as the gold standard for cerebral blood flow evaluation. CT cerebrovascular angiography (CTA) is a noninvasive and widely used examination method that can identify missing or severely reduced cerebral blood flow. However, due to limited experience and lack of sufficient evidence to prove its reliability, it is not included in the AAN A recognized auxiliary examination; there are also a large number of domestic and foreign literature reports that CTA can be used as a new confirmation test for clinical judgment of brain death. This study aims to explore the value of CTA in the judgment of patients with brain death.

Official Title
-----------------
Evaluation of CTA on the Assessment of Brain Death

Conditions
-----------------
Brain Death

Intervention / Treatment
-----------------
* Combination Product: Combination Product
* Other: NO CTA examination


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Recruiting, no definite Exclusion Criteria: Recruiting, no definite

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 72 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CTA examination<br>CTA examination group for suspected brain death | Combination Product: Combination Product<br>* Cases of brain death confirmed by the classic brain death confirmation test<br>|
| Confirmed<br>Confirmed group for brain death | Other: NO CTA examination<br>* NO CTA examination<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CTA used as an auxiliary diagnosis to determine brain death | CTA used as an auxiliary diagnosis to determine brain death | through study completion, an average of 3 years. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
brain death, CT angiography
Feasibility of Total Mastectomy in Ambulatory Care

Study Overview
=================
Brief Summary
-----------------
Breast cancer is the first female cancer in France. Total mastectomy occurred in 30% of breast cancer patient population. The purpose of this study is to evaluate the feasibility of outpatient surgery for the total mastectomy. In France, Ambulatory care is developed as part of the new national health plan. Breast conserving surgery for tumorectomy or partial mastectomy is already done in outpatient vacation. Total mastectomy is an extension of this surgery, and, as such, underpins the investigator's hypothesis that total mastectomy is feasible in outpatient care .

Official Title
-----------------
Feasibility of Total Mastectomy in Ambulatory Care

Conditions
-----------------
Breast Cancer, Mastectomy, Ambulatory Care

Intervention / Treatment
-----------------
* Procedure: total mastectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patient with an indication of breast non conserving surgery Exclusion Criteria: Standard contra-indication for ambulatory care. Also bilateral surgery and immediate breast reconstruction.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: breast cancer mastectomy<br> | Procedure: total mastectomy<br>* breast cancer non conserving surgery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of ambulatory care after total mastectomy allowed with PADSS score | Post Anaesthetic Discharge Scoring System (PADSS), which considers six criteria: vital signs, ambulation, nausea/vomiting, pain, bleeding and voiding. Each criterion is given a score ranging from 0 to 2. Only patients who achieve a score of 9 or more are considered ready for discharge. | day 0= day of surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
mastectomy, Breast Cancer, ambulatory care
Impact of Omalizumab on Corticosteroid Use, Emergency Room Visits and Hospitalizations

Study Overview
=================
Brief Summary
-----------------
A retrospective database analysis to evaluate the impact of omalizumab on the use of corticosteroid, emergency-department visits and hospitalizations among patients with uncontrolled asthma and using high-dose Inhaled Corticosteroids (ICS) prior to initiating omalizumab.

Official Title
-----------------
Analyze the Impact of Omalizumab on Corticosteroid Use, Emergency Room Visits and Hospitalizations Among Patients With Uncontrolled Asthma Receiving High Dose Inhaled Corticosteroids

Conditions
-----------------
Asthma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ≥12 years of age with a documented Cystic fibrosis (CF) diagnosis, on Long acting Beta antagonist- Inhaled Corticosteroid (LABA-ICS) at baseline, uncontrolled asthma at baseline. Exclusion Criteria: Other protocol-defined inclusion/exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Omalizumab Cohort<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of emergency-department visits and hospitalizations |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Asthma, Omalizumab
Breath Volatile Organic Compounds Patterns of Lung Transplant Patients With Chronic Lung Allograft Dysfunction

Study Overview
=================
Brief Summary
-----------------
It's the aim of this study to clarify, whether the non-invasive assessment of breath can serve as a novel clinical tool to assist in the diagnosis of CLAD. If different stages of BOS can be discriminated by the level of certain VOCs than there would also be a potential to actually predict the development at an early stage and would enable an earlier intervention.

Conditions
-----------------
Chronic Lung Allograft Dysfunction (CLAD)

Intervention / Treatment
-----------------
* Other: Collection of exhaled breath volatile organic compounds


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Outpatient bilateral lung transplant recipients including combined transplants Exclusion Criteria: Active Smoking Oxygen therapy Infection with multi or pan-resistant bacteria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Severe<br>Severe chronic lung allograft dysfunction (CLAD), bronchiolitis obliterans syndrome (BOS), stage 3 | Other: Collection of exhaled breath volatile organic compounds<br> <br> |
| Mild<br>Mild chronic lung allograft dysfunction (CLAD), bronchiolitis obliterans syndrome (BOS), stage 1-2 | Other: Collection of exhaled breath volatile organic compounds<br> <br> |
| Control<br>Bronchiolitis obliterans syndrome (BOS), stage 0 | Other: Collection of exhaled breath volatile organic compounds<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Concentration of exhaled breath volatile organic compounds |  | one sample will be collected between 6 month and 20 years after lung transplantation |